This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Do Options Traders Know Something About CareDx Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CDNA stock based on the movements in the options market lately.
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
by Zacks Equity Research
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and -4.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) Tops Q1 Earnings Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 50% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why Community Health's Florida Divestiture Matters
by Zacks Equity Research
Offloading the Punta Gorda facility is expected to remove uncertainty tied to restoration costs and revenue losses for CYH.
New Strong Buy Stocks for February 27th
by Zacks Equity Research
BCS, CDNA, PGR, EZPW and EVER have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2025.
CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pediatrix Medical Group (MD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 37.84% and 3.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CareDx (CDNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 42.3% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Best Momentum Stocks to Buy for January 30th
by Zacks Equity Research
OBK, BBCP and CDNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 30, 2024.
New Strong Buy Stocks for January 30th
by Zacks Equity Research
BBCP, SDVKY, OBK, CDNA and NVAX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.
Is CareDx (CDNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareDx (CDNA) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 21st
by Zacks Equity Research
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
New Strong Buy Stocks for January 21st
by Zacks Equity Research
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
by Zacks Equity Research
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Implied Volatility Surging for CareDx (CDNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.
Here's Why You Should Add Ensign Group Stock to Your Portfolio Now
by Zacks Equity Research
ENSG should benefit from expanding facilities and growing footprint, leading to higher service revenues in the future.
Ensign Expands Footprint With Buyout of Eight Healthcare Facilities
by Zacks Equity Research
ENSG agrees to buy eight healthcare facilities from Providence Home and Community Care, expanding its footprint.
Molina Healthcare Expands Dual Eligible Services in Michigan, Idaho
by Zacks Equity Research
MOH secures key contracts in Michigan and Idaho to expand services for dual-eligible populations, driving growth and strengthening its role in integrated care solutions.
Ensign Group Rewards Shareholders With 4.2% Dividend Hike
by Zacks Equity Research
ENSG hikes quarterly dividend by 4.2%, maintaining its record of raising dividends for the past 22 years.
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
by Zacks Equity Research
CNC expects robust growth in its Medicaid, Marketplace and Medicare businesses. This is likely to be driven by rate increases, rising uninsured individuals and dual expansions.
Community Health to Divest North Carolina Hospital for $280M
by Zacks Equity Research
CYH is selling the 123-bed facility in Mooresville to Duke Health.